

Myeloma Pathways: Multiple Myeloma

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: New diagnosis Relapse

Line of Treatment: First Line Second Line Third Line Third Line+ Maintenance

ECOG Performance Status: 0 1 2 3 4

Biomarker:

Transplant candidate Non-transplant candidate

Primary/ First line of therapy (1st line) | Transplant candidates

VRD/VDR: bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone

Primary/ First line of therapy (1st line) | Ineligible for transplant

CyBORd or VDC: bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone

R-dex: lenalidomide (Revlimid) and low-dose dexamethasone

VRD/VDR: bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone

VD: bortezomib (Velcade) and dexamethasone

Maintenance therapy | Post-transplant

Lenalidomide (Revlimid)

Relapsed disease | Second and subsequent lines of therapy (2nd line+)

CRd or KRd: carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone

DRD: daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone

DVD: daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone

Relapsed disease | Third and subsequent lines of therapy (3rd line+)

Daratumumab (Darzalex)

Elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.